Compare PepsiCo, Inc. (PEP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? PepsiCo, Inc. trades at $137.12 (market cap $188.97B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: PepsiCo, Inc. is far larger — about 10.5× Zimmer Biomet Holdings Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| PEP | ZBH | |
|---|---|---|
Market Cap | $188.97B | $17.97B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $104.26 |
52-Week Low | $134.95 | $79.58 |
Enterprise Value | $231.47B | $25.04B |
Dividend Yield | 4.28% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income declined to $8.24B. Analysts maintain a consensus price target of $158.79 with 33% buy ratings. Recent news highlights price adjustments on snack products and sponsorship changes.
PEP offers stable dividend income and moderate growth potential, but faces margin pressure from input costs and competitive pricing. The stock trades below analyst targets with solid cash flow generation, though technical indicators suggest near-term weakness. Key risks include consumer sensitivity to price increases and execution challenges in North American markets.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
